Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of Aripiprazole Long-acting on Myelin and Cognition in Early Schizophrenia
NCT05322031Phase 4Completed
- Sponsor
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
- Start
- Aug 2022
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of aripiprazole in schizophrenia, sponsored by Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico. Primary endpoint: Brain structural modifications in terms of myelination of the white matter at 3 months. Started Aug 2022; status: completed.
02
Drugs
aripiprazole
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT05322031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05322031.